DrugBiological
Eflapegrastim clinical trials
Also written SPI-2012 and HM10460A.
- studies test it
- 8
- open now
- 2
- in phase 3
- 2
- first study started
- 2009
Keep track of what changes. Save the eflapegrastim studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
8 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
- Phase 3
- 2
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 1
Spectrum Pharmaceuticals, Inc (6) · Hanmi Pharmaceutical Company Limited (1) · Eunseong Medical Foundation Good GANG-AN HOSPITAL (1)
Often tested with
Tested in the same studies.
Pegfilgrastim (3) · Docetaxel (1) · Cyclophosphamide (1) · Antineoplastic Agents (1)
Studies
Open first, then newest update. How each study uses eflapegrastim is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyRecruitingPhase 2Spectrum Pharmaceuticals, IncNCT04570423Written as Eflapegrastim
- Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After ChemotherapyRecruitingPhase 4Eunseong Medical Foundation Good GANG-AN HOSPITALNCT05949333Written as Eflapegrastim
- Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-CancerCompletedPhase 1Spectrum Pharmaceuticals, IncNCT04187898Written as Eflapegrastim
- Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast CancerCompletedPhase 2Spectrum Pharmaceuticals, IncNCT01724866Written as SPI-2012
- SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and CyclophosphamideCompletedPhase 3Spectrum Pharmaceuticals, IncNCT02953340Written as SPI-2012
- SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)CompletedPhase 3Spectrum Pharmaceuticals, IncNCT02643420Written as SPI-2012
- Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) ChemotherapyCompletedPhase 1Spectrum Pharmaceuticals, IncNCT03135951Written as SPI-2012
- Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean SubjectsCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT00998283Written as HM10460A 5μg/kg
Codes
What other systems call eflapegrastim · ClinicalTrials.gg INT006342
- MeSH (NLM) C583329eflapegrastimOne source NLM
- UNII (FDA) UT99UG9QJXEFLAPEGRASTIMConfirmed FDA, NLM, Wikidata
- RxNorm 2612526One source FDA
- Wikidata Q30314101eflapegrastimConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C103856EflapegrastimOne source FDA
- DrugBank DB15001One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583329 | eflapegrastim | One source NLM |
| UNII (FDA) | UT99UG9QJX | EFLAPEGRASTIM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2612526 | — | One source FDA |
| Wikidata | Q30314101 | eflapegrastim | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C103856 | Eflapegrastim | One source FDA |
| DrugBank | DB15001 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.